Abigail Brooks, MA

Findings from the HOPE Consortium Trial suggest PCST can help pain interference and quality of life in patients on hemodialysis experiencing chronic pain.

Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.

From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.

The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLD’s The Liver Meeting

The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.

Study findings suggest outcomes observed with intensive blood pressure targets in SPRINT are transportable to patients with CKD in clinical practice.

Findings suggest the potential value of anti-gliadin and anti-F-actin IgA for risk stratification in patients with primary sclerosing cholangitis.

Systematic review findings point to bias and insufficient clinical applicability with current mortality risk models in patients with kidney failure.

The December month in review spotlights hepatic FDA news as well as the latest research in viral hepatitis and MASH.

The December month in review spotlights top GI pipeline updates, FDA news, a feature, and IBS research from the final month of 2024.

Patients hospitalized for severe COVID-19 had an accelerated eGFR decline relative to those with pneumonia due to other infections.

This year in review spotlights top GI FDA news from 2024 and new clinical guidance from the American Gastroenterological Association.

2024 was a historic year in hepatology, characterized by notable hepatic FDA approvals, pipeline developments, new WHO HBV guidelines, and more.

Resmetirom made history when it became the first and only FDA-approved MASH drug in 2024, but the pipeline continues to show promise heading into 2025.

The proposed rule seeks to establish and require standardized testing methods to detect and identify asbestos in cosmetic products with talc.

Post-hoc analysis findings suggest tenapanor improves both abdominal and bowel symptoms in adult patients with IBS-C.

Gestational exposure to certain NSAIDs during different trimesters of pregnancy was associated with an increased risk of childhood CKD.

Patients with PSC had worse death, transplant, liver-related mortality, and liver-related decompensation outcomes than PBC and autoimmune hepatitis.

The ML model exhibited better predictive performance than previous traditional HCC models in patients with chronic HBV on long-term antiviral therapy.

The phase 2b/3 NAVIGATE trial missed its primary endpoint for the prevention of varices in patients with MASH cirrhosis and portal hypertension.

Retransplantation outcomes were similar or better in patients with PSC compared with patients with other liver disease etiologies.

Frissora reviews findings from a cost-effectiveness analysis comparing the Vibrant System to linaclotide for CIC management.

Study findings suggest the potential utility of ΔADC for assisting the clinical, pathological, and prognostic risk stratification of patients with IgAN.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

The sBLA seeks to expand golimumab’s approval for UC to include pediatric patients ≥ 2 years of age and is supported by data from the PURSUIT program.

Study findings suggest an interplay between social determinants of health and HS, especially among underrepresented patient populations.

Clark reviews open-label extension data from the phase 2b SEQUOIA study of fazirsiran for AATD liver disease.

The Boxed Warning is based on the FDA’s review of a postmarketing case of serious liver injury with fezolinetant reported to the FAERS database.

Positive phase 2b data show duvakitug met primary endpoints for clinical remission in ulcerative colitis and endoscopic response in Crohn disease.